ArticleCurrent neuropharmacology2026
Efgartigimod in Very-Late-Onset Generalized Myasthenia Gravis: A Real-World Study on Effectiveness and Safety.
Article in Current neuropharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efgartigimod-alfa therapy in acetylcholine receptor antibody myasthenia gravis: Romanian experience.Frontiers in neurology · 2026Article
- Real-world study of efgartigimod in AChR antibody-positive generalized myasthenia gravis: thymus status, multi-domain symptom improvement and steroid-sparing effect.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionThis study evaluated the safety and effectiveness of efgartigimod in patients with Very-Late-Onset Generalized Myasthenia Gravis (VLOGMG), a population that often presents with more severe symptoms and limited treatment responses.
methodsForty-two patients aged ≥ 65 years were retrospectively included. Clinical assessments, including MG activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG) scores, prednisone dosage, laboratory data, and adverse events, were recorded at each follow-up.
resultsAt week 4, 97.6% (41/42; 95% CI, 87.4-99.9) of patients were MG-ADL responders (≥ 2- point improvement). Notably, 83.3% (95% CI, 69.4-92.8) maintained response through week 12 (p < 0.001). Clinically meaningful improvement (CMI, ≥3-point QMG decrease) occurred in 97.6% of patients (41/42; 95% CI, 87.4-99.9), with a mean response time of 6.37 ± 5.46 days (95% CI, 4.63- 8.11). Minimal symptom expression (MSE, MG-ADL score of 0 or 1) was achieved in 45% (95% CI, 30-61%), 60% (95% CI, 44-74%), and 45% (95% CI, 30-61%) of patients at weeks 4, 8, and 12, respectively. Prednisone dosage was tapered from a median of 20 (20, 30) mg/day to 10 (5, 15) mg/day by week 12. Most patients (88.1%) had ≥ 1 comorbidity, and 61.9% had multimorbidity. Efgartigimod was well tolerated, without evidence of worsening of pre-existing conditions. DISCUSSION: Efgartigimod provided rapid symptom relief in older adults with VLOGMG and demonstrated steroid-sparing benefits across patients with various comorbidities. The high response rates and sustained improvement suggest that early use of fast-acting therapies may serve as a bridge to conventional long-term treatments. Larger prospective studies are warranted to confirm these findings.
conclusionEfgartigimod is associated with clinical benefit in patients with VLOGMG, allowing corticosteroid reduction without compromising comorbidity stability. Early initiation may enable faster disease control and more durable responses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.